Results 91 to 100 of about 110,023 (239)

Cost‐effectiveness analysis of human papillomavirus (HPV) genotyping strategies for management of HPV‐positive women in cervical cancer screening

International Journal of Cancer, EarlyView.
What's New? Persistent infection with high‐risk human papillomavirus (HPV) causes most invasive cervical cancer cases, leading many countries to transition from cytology to primary HPV‐based screening. Despite the benefits, HPV‐based screening may also lead to unnecessary procedures, psychological burden, and strain on healthcare systems.
Kelsi R. Kroon, Johannes A. Bogaards, Johannes Berkhof   +2 more
wiley   +1 more source

Erratum: Prevalence and distribution of selected cervical human papillomavirus types in HIV infected and HIV uninfected women in South Africa, 1989–2021: A narrative review

Southern African Journal of Infectious Diseases
No abstract available.
Rixongile R. Rikhotso, Emma M. Mitchell, Daniel T. Wilson, Aubrey Doede, Nontokozo D. Matume, Pascal O. Bessong   +5 more
doaj   +1 more source

Health care policy trial of primary human papillomavirus–based cervical screening in Denmark: Comparison of three triage algorithms

International Journal of Cancer, EarlyView.
What's New? Primary human papillomavirus (HPV)–based screening has shown superiority to cytology‐based screening in reducing cervical cancer risk in clinical trials. However, the benefit must be balanced with potential overdiagnosis/overtreatment.
Jeppe Bennekou Schroll, Jesper Bonde, Elsebeth Lynge, Marianne Waldstrøm, Petra Hall Viborg, Anna Frandsen, Rikke Holst Andersen, Susanne Merete Nielsen, Bettina Kjær Kristensen, Doris Schledermann, Berit Andersen, on behalf ofthe National Danish Cervical Cancer Screening Steering Committee   +11 more
wiley   +1 more source

Transitioning from HPV 101 to HPV 202 [PDF]

American Journal of Obstetrics and Gynecology, 2017
Warner K, Huh, Richard, Guido
openaire   +2 more sources

Nonavalent HPV vaccine to prevent recurrent anal or vulvar high‐grade squamous intraepithelial lesions (VIVA trial): A randomized, double‐blind, placebo‐controlled trial

International Journal of Cancer, EarlyView.
What's New? Anal and vulvar high‐grade squamous intraepithelial lesions (HSILs) frequently recur following treatment. Additional genital and anal procedures, however, can be distressing for patients and are potentially disfiguring. This trial assessed whether the 9‐valent human papillomavirus (9vHPV) vaccine reduces HSIL recurrence risk or HPV ...
Helen C. Stankiewicz Karita, Amalia S. Magaret, David R. Doody, Jeffrey T. Schouten, Constance Mao, Warner K. Huh, Verena S. Grieco, Matthew A. Seymour, Dana Varon, Kelly H. Shrader, Long Fu Xi, Denise A. Galloway, Anna Wald, Margaret M. Madeleine   +13 more
wiley   +1 more source

Post‐surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detection

International Journal of Cancer, EarlyView.
What's New? Circulating nuclear DNA (cir‐nDNA)‐based assessment of minimal residual disease (MRD) offers powerful post‐surgery prognostic insight for stage III colon cancer (CC). Sparse knowledge of post‐surgical variations and origins in cir‐nDNA, however, has limited its clinical application.
Andrei Kudriavtsev, Saidi Daoud, Catalina Isabel Cofre Muñoz, Alexia Mirandola, Ekaterina Pisareva, Javier Gonzalo Ruiz, Marco Macagno, Nadia Saoudi Gonzalez, Evelyne Crapez, Marc Ychou, Ramon Salazar Soler, Elisabetta Fenocchio, Paula X. Fernandez Calotti, Thibault Mazard, Cristina Santos Vivas, Elena Elez, Federica Di Nicolantonio, Alain R. Thierry   +17 more
wiley   +1 more source

Increased cervical cancer incidence in the target age of screening—Variation by mode of detection

International Journal of Cancer, EarlyView.
What's New? Cervical cancer rates have risen in several high‐income countries despite advances in screening. Here, using data on cervical cancer diagnoses between 1996 and 2022 in Finland, the authors examined incidence trends according to detection mode—screening, between screenings, or outside screening programs—with attention to the role of human ...
Jenna Snellman, Maiju Pankakoski, Sirpa Heinävaara, Veli‐Matti Partanen, Maija Vahteristo   +4 more
wiley   +1 more source

Cost‐effectiveness of risk‐stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage

International Journal of Cancer, EarlyView.
What's New? Effective cervical cancer prevention centers around screening and testing for human papillomavirus (HPV) infection. With birth cohorts of HPV‐vaccinated women now reaching screening‐eligible ages, however, the best means to maintaining cost‐effective cervical cancer screening is unclear.
Tiago M. de Carvalho, Johannes Berkhof, Johannes A. Bogaards   +2 more
wiley   +1 more source

Antiviral regulator TRIM25 as a prognostic marker of better survival in Merkel cell carcinoma: Association with MCPyV status

International Journal of Cancer, EarlyView.
What's New? TRIM25 is known for its role in antiviral immunity and association with poor prognosis in various cancers. This study reveals an association between high TRIM25 expression and Merkel cell polyomavirus positivity in Merkel cell carcinoma.
Klaus W. Fagerstedt, Sami Kilpinen, Johanna Arola, Benjamin Z. Sundqvist, Tom Böhling, Leif C. Andersson, Harri Sihto   +6 more
wiley   +1 more source

The effect of making a ‘third dose assumption’ on HPV coverage estimates

Australian and New Zealand Journal of Public Health, 2015
Julia M. Brotherton, Karen Winch
doaj   +1 more source